217 related articles for article (PubMed ID: 21827391)
1. Immunotherapy and targeted therapy combinations in renal cancer.
McDermott DF
Curr Clin Pharmacol; 2011 Aug; 6(3):207-13. PubMed ID: 21827391
[TBL] [Abstract][Full Text] [Related]
2. What is standard initial systemic therapy in metastatic renal cell carcinoma?
Rini BI; McDermott D; Atkins M
Clin Genitourin Cancer; 2007 Mar; 5(4):256-63. PubMed ID: 17553205
[TBL] [Abstract][Full Text] [Related]
3. VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective.
Choueiri TK
Curr Clin Pharmacol; 2011 Aug; 6(3):164-8. PubMed ID: 21827394
[TBL] [Abstract][Full Text] [Related]
4. Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development.
Rasmussen N; Rathmell WK
Curr Clin Pharmacol; 2011 Aug; 6(3):199-206. PubMed ID: 21470103
[TBL] [Abstract][Full Text] [Related]
5. Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents.
Porta C; Toscani I; Czarnecka AM; Szczylik CA
Expert Opin Biol Ther; 2017 Feb; 17(2):151-162. PubMed ID: 27960591
[TBL] [Abstract][Full Text] [Related]
6. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.
Considine B; Hurwitz ME
Curr Oncol Rep; 2019 Mar; 21(4):34. PubMed ID: 30848378
[TBL] [Abstract][Full Text] [Related]
7. Sequential use of targeted agents in the treatment of renal cell carcinoma.
Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
[TBL] [Abstract][Full Text] [Related]
8. Kidney cancer therapy: new perspectives and avenues.
Alexandrescu DT; Dasanu CA
Expert Opin Pharmacother; 2006 Dec; 7(18):2481-93. PubMed ID: 17150003
[TBL] [Abstract][Full Text] [Related]
9. Toxicities of targeted agents in advanced renal cell carcinoma.
Patel P; Srinivas S
Curr Clin Pharmacol; 2011 Aug; 6(3):181-8. PubMed ID: 21827392
[TBL] [Abstract][Full Text] [Related]
10. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy.
Bedke J; Gouttefangeas C; Singh-Jasuja H; Stevanović S; Behnes CL; Stenzl A
World J Urol; 2014 Feb; 32(1):31-8. PubMed ID: 23404195
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
13. Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents.
Porta C; Paglino C; Imarisio I; Bonomi L
ScientificWorldJournal; 2007 Apr; 7():837-49. PubMed ID: 17619768
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of metastatic renal cell carcinoma.
McDermott DF; Atkins MB
Cancer J; 2008; 14(5):320-4. PubMed ID: 18836337
[TBL] [Abstract][Full Text] [Related]
15. Perspectives in drug development for metastatic renal cell cancer.
Basu B; Eisen T
Target Oncol; 2010 Jun; 5(2):139-56. PubMed ID: 20689997
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
17. The Immunotherapy Revolution in Kidney Cancer Treatment: Scientific Rationale and First-Generation Results.
Hasanov E; Gao J; Tannir NM
Cancer J; 2020; 26(5):419-431. PubMed ID: 32947310
[TBL] [Abstract][Full Text] [Related]
18. Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma.
Ryan CW
J Oncol Pharm Pract; 2017 Jan; 23(1):43-55. PubMed ID: 26625878
[TBL] [Abstract][Full Text] [Related]
19. Targeted treatment for metastatic renal cell carcinoma and immune regulation.
Laschos KA; Papazisis KT; Kontovinis LF; Kalaitzis C; Gianakopoulos S; Kortsaris AH; Touloupidis S
J BUON; 2010; 15(2):235-40. PubMed ID: 20658715
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
